Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide yellow; brilliant blue fcf aluminium lake; polacrilin potassium; magnesium stearate - oral contraception

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ethinylestradiol, quantity: 0.02 mg; levonorgestrel, quantity: 0.1 mg - tablet - excipient ingredients: povidone; croscarmellose sodium; iron oxide yellow; magnesium stearate; brilliant blue fcf aluminium lake; microcrystalline cellulose; lactose monohydrate - lenest 20 ed is indicated for the prevention of pregnancy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: povidone; titanium dioxide; magnesium stearate; maize starch; hypromellose; polysorbate 80; triacetin; indigo carmine aluminium lake; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate - oral contraception

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 36 microgram; norethisterone, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications as at 31 august 1998 : contraception

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 500 microgram; ethinylestradiol, quantity: 36 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose; sunset yellow fcf; lactose monohydrate - 31 august 1998 : contraception

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 1 mg; mestranol, quantity: 51.5 microgram - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; maize starch; magnesium stearate - indications as at 23rd january 1998: oral contraception. norinyl-1 is an agent for conception control.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 1 mg; ethinylestradiol, quantity: 36 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications as at 31 august 1998 : contraception

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 36 microgram; norethisterone, quantity: 500 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; sunset yellow fcf; magnesium stearate; microcrystalline cellulose; lactose - indications as at 31 august 1998 : contraception

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.